Iranian experience of deferasirox (exjadespi®) in transfusion-dependent patients with iron overload: What is the most effective dose based on serum ferritin levels?

Hematology

Volumn 17, Issue 6, 2012, Pages 367-371

  Karimi, Mehran ^a   Azarkeivan, Azita ^b   Zareifar, Soheila ^b   Cohan, Nader ^a   Bordbar, Mohammad Reza ^a   Haghpanah, Sezaneh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

Author keywords

Deferasirox; Efficacy; Exjade; Iran; Iron overload

Indexed keywords

DEFERASIROX; FERRITIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; BLOOD TRANSFUSION; CHILD; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IRAN; IRON OVERLOAD; KIDNEY DISEASE; LEUKOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN MANIFESTATION; THALASSEMIA MAJOR; UREA NITROGEN BLOOD LEVEL; URINE PROTEIN CREATININE RATIO; UROGENITAL SYSTEM PARAMETERS; VOMITING;

ADOLESCENT; ADULT; BENZOATES; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84869752836     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1024533212Z.000000000143     Document Type: Article

References (22)

1. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-52.
2. Ramzi M, Nourani H, Zakernia M, Hamidian Jahromi AR. Hematopoietic stem cell transplantation for beta-thalassemia major: experience in south of Iran. Transplant Proc. 2004;36: 2509-10.
3. Ramzi M, Nourani H, Zakernia M, Dehghani M, Vodjani R, Haghshenas M. Results of hematopoietic stem cell transplant in Shiraz: 15 years experience in Southern Iran. Exp Clin Transplant. 2010;8:61-5.
4. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chela- tordeferiprone. Blood. 2003;102:1583-7.
5. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-6.
6. Zareifar S, Jabberi A, Cohan N, Haghpanah S. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxa- mine therapy in patients with major thalassemia. Arch Iran Med. 2009;12:488-91.
7. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol. 2009;122:155-64.
8. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann NY Acad Sci. 2010; 1202:79-86.
9. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators: from desfer- rithiocin to ICL670. Curr Med Chem. 2003;10:1065-76.
10. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-80.
11. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta thalassemia major. Haematologica. 2006;91:1343-51.
12. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelo- dysplastic syndromes and other transfusion dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-76.
13. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, et al. Importance of optimal dosing >30 mg/kg/day during defera- sirox treatment: 2.7-year follow-up from the ESCALATOR study in patients with p-thalassaemia. Eur J Haematol. 2011; 87:355-65.
14. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during years' follow-up. Blood. 2011;118:884-93.
15. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, et al. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154: 387-97.
16. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. On behalf of the EPIC study investigators: tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95: 557-66.
17. Karimi M, Johari SH, Cohan N. Attitude toward prenatal diagnosis for p-thalassemia major and medical abortion in southern Iran. Hemoglobin. 2010;34:49-54.
18. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with p-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65.
19. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29: 909-17.
20. Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119: 133-41.
21. Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49:329-32.
22. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93: 1584-6.